Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Current Deferred Revenue (2022 - 2025)

IceCure Medical (ICCM) has disclosed Current Deferred Revenue for 3 consecutive years, with $334000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue rose 78.61% to $334000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $334000.0, a 78.61% increase, with the full-year FY2024 number at $334000.0, up 78.61% from a year prior.
  • Current Deferred Revenue was $334000.0 for Q4 2024 at IceCure Medical, up from $187000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $646000.0 in Q4 2022 to a low of $187000.0 in Q4 2023.
  • A 3-year average of $389000.0 and a median of $334000.0 in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: tumbled 71.05% in 2023, then surged 78.61% in 2024.
  • IceCure Medical's Current Deferred Revenue stood at $646000.0 in 2022, then crashed by 71.05% to $187000.0 in 2023, then soared by 78.61% to $334000.0 in 2024.
  • Per Business Quant, the three most recent readings for ICCM's Current Deferred Revenue are $334000.0 (Q4 2024), $187000.0 (Q4 2023), and $646000.0 (Q4 2022).